H3 Biomedicine has opened a new headquarters and 24,000 square feet of state-of-the-art laboratory space in Cambridge, Massachusetts. Over the next year, the company plans to increase its staff to 70 people and further expand into more laboratory space within its building as it continues to pursue its mission to fulfill the promise of personalized cancer medicine.

"H3 Biomedicine is well equipped with our new Cambridge facilities to address some of the most challenging cancers by delivering on our scientific vision of patient-based, genomics-driven drug discovery," said Markus Warmuth, M.D., H3 Biomedicine president and CEO.

H3 Biomedicine's scientific vision was established by scientific founders Dr. Stuart Schreiber and Dr. Todd Golub of the Broad Institute of Harvard and MIT. The vision is based on their understanding that the genetics of patients' cancers can reveal drug targets tailored to their cancers, and when you add the advances in next-generation synthetic chemistry it will enable the discovery of new classes of drugs against these targets. Eisai, a leading global pharmaceutical company, has pledged up to $200 million in research funding to H3 Biomedicine and will provide additional support for the H3 clinical development programs including access to many of Eisai's drug development capabilities.

"Our commitment is based on our belief that H3 Biomedicine provides an innovative, intensely collaborative business model ideally suited to the intellectual, operational, and fiscal demands of genomics-driven, patient-based drug discovery," said Haruo Naito, Eisai president and CEO.